Pharmacologic Treatment of Cancer: New Developments
نویسندگان
چکیده
منابع مشابه
Pharmacologic Treatment of Cancer: New Developments.
In this issue of Cancer Control, five reviews address the current state of the art for the pharmacologic treatment of cancer. For centuries, surgery was considered the only curative treatment for cancer. Likewise, radiation therapy offered some patients a possible cure for cancers that were localized. However, once the disease spread from its original site of origin, the patient was deemed inop...
متن کاملNew developments in the pharmacologic treatment of schizophrenia: editor's introduction.
In this issue we have tried to bring together a series of reviews describing new developments in the pharmacologic management of schizophrenia. Important progress is being made not only in medication development, but also in furthering our ability to use available treatments and treatment combinations in the most effective manner. Topics discussed include: the role of blood levels; alternative ...
متن کاملCurrent Developments in the Pharmacologic Treatment of Psychotic Disorders*
The pharmacologic management of schizophrenia has dramatically improved over the past 50 years. While the first-generation, or conventional, antipsychotic medications were found to be helpful in reducing the positive symptoms of the disorder, they had little effect on negative and cognitive symptoms. Additionally, the first-generation agents were associated with the troubling neurologic side ef...
متن کاملCardiorenal syndrome: new developments in the understanding and pharmacologic management.
Cardiorenal syndromes (CRSs) with bidirectional heart-kidney signaling are increasingly being recognized for their association with increased morbidity and mortality. In acute CRS, recognition of the importance of worsening kidney function complicating management of acute decompensated heart failure has led to the examination of this specific outcome in the context of acute heart failure clinic...
متن کاملNew developments in the treatment of HER2-positive breast cancer.
Approximately 20%-30% of metastatic breast cancers show increased expression of the human epidermal growth factor receptor-2 (HER2) tyrosine kinase. Two HER2-specific therapies are currently approved for clinical treatment of patients with HER2-overexpressing metastatic breast cancer. Trastuzumab is a monoclonal antibody against HER2 and is approved for first-line treatment of HER2-positive met...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Control
سال: 1999
ISSN: 1073-2748,1073-2748
DOI: 10.1177/107327489900600511